Patents by Inventor Ulrike Samulowitz
Ulrike Samulowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180171338Abstract: The present invention relates generally to immunostimulatory nucleic acids, compositions thereof and methods of using the immunostimulatory nucleic acids. In particular the invention relates to palindrome-containing immunostimulatory nucleic acids and the use of these nucleic acids in treating disease.Type: ApplicationFiled: February 5, 2018Publication date: June 21, 2018Applicant: Adiu Tide Pharmaceuticals GmbHInventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg, Ulrike Samulowitz, Bernard O. Noll
-
Patent number: 8304396Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: GrantFiled: October 4, 2006Date of Patent: November 6, 2012Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbH, Pfizer Inc.Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann, Marion Jurk, Grayson B. Lipford, Robert Rankin
-
Patent number: 8283328Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: GrantFiled: August 19, 2003Date of Patent: October 9, 2012Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Grayson Lipford, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann, Marion Jurk, Robert Rankin
-
Publication number: 20120219571Abstract: Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5? TCGTCGTTTTCGGCGCGCGCCGT 3? (SEQ ID NO: 1), in which each C is unmethylated and 3? refers to the 3? end of the nucleic acid. The oligonucleotides activate B cells and NK cells and induce expression of type I interferon and interferon-?. The oligonucleotides are useful for treating a variety of disorders and conditions, including allergy, asthma, infection, and cancer. In addition to their use as single agents and as combination therapies, the disclosed oligonucleotides are useful as adjuvants in vaccines.Type: ApplicationFiled: May 14, 2012Publication date: August 30, 2012Applicants: COLEY PHARMACEUTICAL GMBH, PFIZER INC, COLEY PHARMACEUTICAL GROUP, INC.Inventors: JORG VOLLMER, EUGEN UHLMANN, ARTHUR M. KRIEG, DOUGLAS C. HANSON, ULRIKE SAMULOWITZ
-
Patent number: 8198251Abstract: Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5? TCGTCGTTTTCGGCGCGCGCCGT 3? (SEQ ID NO: 1), in which each C is unmethylated and 3? refers to the 3? end of the nucleic acid. The oligonucleotides activate B cells and NK cells and induce expression of type I interferon and interferon-?. The oligonucleotides are useful for treating a variety of disorders and conditions, including allergy, asthma, infection, and cancer. In addition to their use as single agents and as combination therapies, the disclosed oligonucleotides are useful as adjuvants in vaccines.Type: GrantFiled: August 12, 2008Date of Patent: June 12, 2012Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc., Pfizer IncInventors: Jorg Vollmer, Eugen Uhlmann, Arthur M. Krieg, Douglas C. Hanson, Ulrike Samulowitz
-
Publication number: 20110201672Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: ApplicationFiled: September 14, 2010Publication date: August 18, 2011Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Patent number: 7795235Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: December 17, 2008Date of Patent: September 14, 2010Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Patent number: 7566703Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: October 20, 2005Date of Patent: July 28, 2009Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Publication number: 20090137519Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: ApplicationFiled: December 17, 2008Publication date: May 28, 2009Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann
-
Publication number: 20090087446Abstract: Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5? TCGTCGTTTTCGGCGCGCGCCGT 3? (SEQ ID NO: 1), in which each C is unmethylated and 3? refers to the 3? end of the nucleic acid. The oligonucleotides activate B cells and NK cells and induce expression of type I interferon and interferon-?. The oligonucleotides are useful for treating a variety of disorders and conditions, including allergy, asthma, infection, and cancer. In addition to their use as single agents and as combination therapies, the disclosed oligonucleotides are useful as adjuvants in vaccines.Type: ApplicationFiled: August 12, 2008Publication date: April 2, 2009Inventors: JORG VOLLMER, Eugen Uhlmann, Arthur M. Krieg, Douglas C. Hanson, Ulrike Samulowitz
-
Publication number: 20080045473Abstract: The present invention relates generally to immunostimulatory nucleic acids, compositions thereof and methods of using the immunostimulatory nucleic acids. In particular the invention relates to palindrome-containing immunostimulatory nucleic acids and the use of these nucleic acids in treating disease.Type: ApplicationFiled: February 15, 2007Publication date: February 21, 2008Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Eugen Uhlmann, Jorg Vollmer, Arthur Krieg, Ulrike Samulowitz, Bernhard Noll
-
Publication number: 20080009455Abstract: The invention relates to a class of short CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. Preferably the short oligonucleotides are soft or semi-soft oligonucleotides.Type: ApplicationFiled: February 24, 2006Publication date: January 10, 2008Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur Krieg, Ulrike Samulowitz, Jorg Vollmer
-
Publication number: 20070224210Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: ApplicationFiled: October 4, 2006Publication date: September 27, 2007Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur Krieg, Grayson Lipford, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann, Marion Jurk, Robert Rankin
-
Publication number: 20060211644Abstract: The invention relates to a class of short CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. Preferably the short oligonucleotides are soft or semi-soft oligonucleotides.Type: ApplicationFiled: February 24, 2006Publication date: September 21, 2006Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur Krieg, Ulrike Samulowitz, Jorg Vollmer
-
Publication number: 20060140875Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: ApplicationFiled: October 20, 2005Publication date: June 29, 2006Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur Krieg, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann
-
Publication number: 20050059619Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: ApplicationFiled: August 19, 2003Publication date: March 17, 2005Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur Krieg, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann, Marion Jurk, Grayson Lipford, Robert Rankin